StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 04-24 | $0.09 | $0.09 | +0.00% | 0.0M |
| 05-05 | $0.09 | $0.09 | +0.00% | 0.1M |
| 05-08 | $0.08 | $0.08 | +0.00% | 0.0M |
| 05-13 | $0.09 | $0.09 | -4.76% | 0.0M |
| 05-14 | $0.09 | $0.08 | -7.78% | 0.0M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Q3 2022 2022-09-30 | Q2 2022 2022-06-30 | Q1 2022 2022-03-31 | Annual 2021 2021-12-31 |
|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
Operating Income | $-234.29K | $-164.30K | $-93.50K | $-325.39K |
Net Income | $-254.17K | $-77.57K | $-98.91K | $-298.63K |
EPS (Diluted) | $0.00 | $0.00 | $0.00 | $0.00 |
Total Assets | $63.12K | $38.52K | $61.14K | $58.78K |
Total Liabilities | $4.09M | $3.94M | $3.83M | $3.68M |
Cash & Equivalents | $53.06K | $24.95K | $36.44K | $30.63K |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available |
Shares Outstanding | 376.86M | 376.86M | 376.86M | 376.86M |
No sell-side coverage available for INTI.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
INHIBITOR THERAPTICS INC